Arrowhead Debt To Equity from 2010 to 2024
| ARWR Stock | USD 26.15 5.10 24.23% |
Debt To Equity | First Reported 2010-12-31 | Previous Quarter 0.63290805 | Current Value 0.6 | Quarterly Volatility 15.2193993 |
Check Arrowhead Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arrowhead Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 15.1 M, Interest Expense of 30.7 M or Selling General Administrative of 93.8 M, as well as many indicators such as Price To Sales Ratio of 686, Dividend Yield of 0.0 or PTB Ratio of 13.14. Arrowhead financial statements analysis is a perfect complement when working with Arrowhead Pharmaceuticals Valuation or Volatility modules.
Arrowhead | Debt To Equity |
Latest Arrowhead Pharmaceuticals' Debt To Equity Growth Pattern
Below is the plot of the Debt To Equity of Arrowhead Pharmaceuticals over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Arrowhead Pharmaceuticals' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arrowhead Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.17 % | 10 Years Trend |
|
Debt To Equity |
| Timeline |
Arrowhead Debt To Equity Regression Statistics
| Arithmetic Mean | 5.93 | |
| Coefficient Of Variation | 256.78 | |
| Mean Deviation | 9.99 | |
| Median | 0.03 | |
| Standard Deviation | 15.22 | |
| Sample Variance | 231.63 | |
| Range | 43.8017 | |
| R-Value | 0.15 | |
| Mean Square Error | 243.66 | |
| R-Squared | 0.02 | |
| Significance | 0.59 | |
| Slope | 0.52 | |
| Total Sum of Squares | 3,243 |
Arrowhead Debt To Equity History
About Arrowhead Pharmaceuticals Financial Statements
Arrowhead Pharmaceuticals shareholders use historical fundamental indicators, such as Debt To Equity, to determine how well the company is positioned to perform in the future. Although Arrowhead Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Arrowhead Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arrowhead Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.63 | 0.60 |
Pair Trading with Arrowhead Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Arrowhead Stock
| 0.45 | BHC | Bausch Health Companies | PairCorr |
| 0.36 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.36 | GANX | Gain Therapeutics | PairCorr |
| 0.34 | HCM | HUTCHMED DRC | PairCorr |
The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.
The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.